Leflunomide exposure through second trimester of pregnancy: A case report.

Leflunomide is a commonly used disease modifying antirheumatic agent. However, its use is contraindicated in pregnancy. The American College of Rheumatology (ACR) guidelines recommend discontinuing Leflunomide at least 24 months before conception. If a woman is found to be pregnant while on Leflunomide, ACR suggests close monitoring and cholestyramine washout. We describe a case of a patient with a history of juvenile idiopathic arthritis who was on Leflunomide throughout the first and second trimester of her pregnancy. A cholestyramine washout regimen was started but not completed. The patient was induced at 37 weeks of gestation due to non-reassuring fetal heart rate. She ultimately delivered a healthy baby via emergency cesarian section.

Saudi Diabetic Patients' Attitudes Towards Patient Portal Use and Their Perceived E-Health Literacy.

A cross-sectional study (n = 130) was conducted to identify diabetic patient's attitudes, patient portal feature preferences, and e-health literacy at two tertiary hospitals in Riyadh, Saudi Arabia. 51% of patients had positive attitude towards the patient portal, 82% think a portal could help with self-care management. 53% of patients had low e-health literacy levels and 9% had high e-health literacy levels. The majority of the study sample have a positive attitude with low e-health literacy levels.